F Balkwill

Summary

Affiliation: Cancer Research UK
Country: UK

Publications

  1. ncbi request reprint Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity
    Sandra J Strauss
    Cancer Research UK Medical Oncology Unit, St Bartholomew s Hospital, W Smithfield, London, United Kingdom
    J Clin Oncol 24:2105-12. 2006
  2. ncbi request reprint Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose
    Michelle L Harrison
    Department of Medicine, Royal Marsden Hospital, London, United Kingdom
    J Clin Oncol 25:4542-9. 2007
  3. ncbi request reprint Smoldering and polarized inflammation in the initiation and promotion of malignant disease
    Frances Balkwill
    Cancer Research UK, Translational Oncology Laboratory, Barts and The London, Queen Mary s Medical School, EC1M 6BQ London, United Kingdom
    Cancer Cell 7:211-7. 2005
  4. ncbi request reprint The significance of cancer cell expression of the chemokine receptor CXCR4
    Fran Balkwill
    Translational Oncology Laboratory, Barts and The London, Queen Mary s Medical School, London EC1M 6BQ, UK
    Semin Cancer Biol 14:171-9. 2004
  5. ncbi request reprint Cancer and the chemokine network
    Fran Balkwill
    Cancer Research UK Translational Oncology Laboratory, Barts and The London, Queen Mary s Medical School, Charterhouse Square, London EC1M 6BQ, UK
    Nat Rev Cancer 4:540-50. 2004
  6. ncbi request reprint Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust
    F Balkwill
    Cancer Research UK, Queen Mary s School of Medicine and Dentistry, EC1M 6BQ London, UK
    Eur J Cancer 39:1818-27. 2003
  7. ncbi request reprint Immunology for the next generation
    Fran Balkwill
    Cancer Research UK Translational Oncology Laboratory, Barts and The London, Queen Mary s School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK
    Nat Rev Immunol 5:509-12. 2005
  8. ncbi request reprint Chemokine biology in cancer
    Fran Balkwill
    Cancer Research UK, Translational Oncology Laboratory Barts, The London Charterhouse Square, Queen Mary s Medical School, London EC1M 6BQ, UK
    Semin Immunol 15:49-55. 2003
  9. ncbi request reprint TNF-alpha in promotion and progression of cancer
    Frances Balkwill
    Institute of Cancer and the CR UK Clinical Centre, Barts and The London, Queen Mary s School of Medicine and Dentistry, 3rd Floor, John Vane Science Centre, Charterhouse Square, London, EC1M 6BQ, UK
    Cancer Metastasis Rev 25:409-16. 2006
  10. ncbi request reprint Tumour necrosis factor and cancer
    Frances Balkwill
    Centre for Cancer and Inflammation, Institute of Cancer, Barts, UK
    Nat Rev Cancer 9:361-71. 2009

Collaborators

Detail Information

Publications25

  1. ncbi request reprint Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity
    Sandra J Strauss
    Cancer Research UK Medical Oncology Unit, St Bartholomew s Hospital, W Smithfield, London, United Kingdom
    J Clin Oncol 24:2105-12. 2006
    ..To determine the efficacy of bortezomib in patients with lymphoid malignancy, correlating clinical response with effect on plasma cytokines and in vitro activity in primary cultures...
  2. ncbi request reprint Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose
    Michelle L Harrison
    Department of Medicine, Royal Marsden Hospital, London, United Kingdom
    J Clin Oncol 25:4542-9. 2007
    ..We performed two sequential phase II studies of infliximab, an anti-TNF-alpha monoclonal antibody, in patients with immunotherapy-resistant or refractory RCC...
  3. ncbi request reprint Smoldering and polarized inflammation in the initiation and promotion of malignant disease
    Frances Balkwill
    Cancer Research UK, Translational Oncology Laboratory, Barts and The London, Queen Mary s Medical School, EC1M 6BQ London, United Kingdom
    Cancer Cell 7:211-7. 2005
  4. ncbi request reprint The significance of cancer cell expression of the chemokine receptor CXCR4
    Fran Balkwill
    Translational Oncology Laboratory, Barts and The London, Queen Mary s Medical School, London EC1M 6BQ, UK
    Semin Cancer Biol 14:171-9. 2004
    ..However CXCR4 plays major roles in embryogenesis, homeostasis and inflammation. This raises questions concerning the specificity of CXCR4 antagonists in the treatment of cancer...
  5. ncbi request reprint Cancer and the chemokine network
    Fran Balkwill
    Cancer Research UK Translational Oncology Laboratory, Barts and The London, Queen Mary s Medical School, Charterhouse Square, London EC1M 6BQ, UK
    Nat Rev Cancer 4:540-50. 2004
  6. ncbi request reprint Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust
    F Balkwill
    Cancer Research UK, Queen Mary s School of Medicine and Dentistry, EC1M 6BQ London, UK
    Eur J Cancer 39:1818-27. 2003
    ..In particular, we highlight the potential of international collaborations in translating laboratory science into useful clinical interventions...
  7. ncbi request reprint Immunology for the next generation
    Fran Balkwill
    Cancer Research UK Translational Oncology Laboratory, Barts and The London, Queen Mary s School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK
    Nat Rev Immunol 5:509-12. 2005
    ..This article is a personal account of one scientist's experience of communicating biomedical science to young people...
  8. ncbi request reprint Chemokine biology in cancer
    Fran Balkwill
    Cancer Research UK, Translational Oncology Laboratory Barts, The London Charterhouse Square, Queen Mary s Medical School, London EC1M 6BQ, UK
    Semin Immunol 15:49-55. 2003
    ..Detailed study of chemokine and chemokine receptor antagonists in experimental cancer models is warranted. Manipulation of the tumor chemokine network could have therapeutic potential in malignant disease...
  9. ncbi request reprint TNF-alpha in promotion and progression of cancer
    Frances Balkwill
    Institute of Cancer and the CR UK Clinical Centre, Barts and The London, Queen Mary s School of Medicine and Dentistry, 3rd Floor, John Vane Science Centre, Charterhouse Square, London, EC1M 6BQ, UK
    Cancer Metastasis Rev 25:409-16. 2006
    ..This article will discuss the involvement of TNF-alpha in the inflammatory network that contributes to all stages of the malignant process, and consider the possibility that TNF-alpha may be a target for cancer therapy...
  10. ncbi request reprint Tumour necrosis factor and cancer
    Frances Balkwill
    Centre for Cancer and Inflammation, Institute of Cancer, Barts, UK
    Nat Rev Cancer 9:361-71. 2009
    ..Now that links between inflammation and cancer are appreciated, is TNF a target or a therapeutic in malignant disease -- or both?..
  11. ncbi request reprint Multiple molecular and cellular changes associated with tumour stasis and regression during IL-12 therapy of a murine breast cancer model
    S Dias
    Biological Therapies Laboratory, Imperial Cancer Research Fund, London, UK
    Int J Cancer 75:151-7. 1998
    ..Comparison of IL-12 and IFN-gamma suggests that sustained induction of IP-10 and activation of a resulting cellular infiltrate may be key changes in regressing tumours...
  12. doi request reprint Cancer and inflammation: implications for pharmacology and therapeutics
    F Balkwill
    Centre for Cancer and Inflammation, Institute of Cancer, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
    Clin Pharmacol Ther 87:401-6. 2010
    ..Smoldering, nonresolving inflammation is a component of the tumor microenvironment. The linkage between inflammation and cancer, first perceived in the nineteenth century, is now part of an accepted paradigm of carcinogenesis...
  13. ncbi request reprint IL-12 regulates VEGF and MMPs in a murine breast cancer model
    S Dias
    Biological Therapies Laboratory, Imperial Cancer Research Fund, London, UK
    Int J Cancer 78:361-5. 1998
    ..Thus, we suggest that at least 2 mechanisms are involved in IL-12 regulation of angiogenesis, removing the pro-angiogenic stimulus and blocking the release and activity of MMPs...
  14. pmc Inflammation and cancer: a double-edged sword
    Thorsten Hagemann
    Centre for Translational Oncology, Institute of Cancer and CR UK Clinical Centre, Barts and The London Queen Mary s School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK
    Cancer Cell 12:300-1. 2007
    ..Apetoh et al. describe how activation of innate immunity after conventional radiation or chemotherapy can trigger protective antitumor immunity...
  15. ncbi request reprint A novel function of colony-stimulating factor 1 receptor in hTERT immortalization of human epithelial cells
    N F Li
    The Centre for Cancer and Inflammation, Institute of Cancer and the Cancer Research UK Clinical Centre, Barts and the London School of Medicine and Dentistry, London, UK
    Oncogene 28:773-80. 2009
    ..On the basis of these findings, we suggest that CSF1R may be a critical factor facilitating hTERT immortalization of epithelial cells...
  16. ncbi request reprint Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis
    R J Moore
    Biological Therapy Laboratory, Imperial Cancer Research Fund, London, UK
    Nat Med 5:828-31. 1999
    ..Strategies that neutralize TNF-alpha production may be useful in cancer treatment and prevention...
  17. pmc Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours
    C Scotton
    ICRF Translational Oncology Laboratory, St Bartholomew s and Royal London School of Medicine and Dentistry, Science Building, Charterhouse Square, London EC1M 6BQ, UK
    Br J Cancer 85:891-7. 2001
    ..The leukocyte infiltrate may contribute to tumour growth and spread by providing growth survival factors and matrix metalloproteases. Thus, CCR1 may be a novel therapeutic target in ovarian cancer...
  18. ncbi request reprint Cancer. Sex, cytokines, and cancer
    Toby Lawrence
    Centre for Translational Oncology, Institute of Cancer, Barts and the London School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK
    Science 317:51-2. 2007
  19. pmc The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells
    Hagen Kulbe
    Centre for Translational Oncology, Institute of Cancer and the Cancer Research UK Clinical Centre and Bone and Joint Research Unit, William Harvey Research Institute, Barts and The London, Queen Mary s School of Medicine and Dentistry, United Kingdom
    Cancer Res 67:585-92. 2007
    ....
  20. ncbi request reprint Cancer-related inflammation
    Alberto Mantovani
    Istituto Clinico Humanitas IRCCS, Via Manzoni 56, Rozzano, 20089 Milan, Italy
    Nature 454:436-44. 2008
    ..The molecular pathways of this cancer-related inflammation are now being unravelled, resulting in the identification of new target molecules that could lead to improved diagnosis and treatment...
  21. ncbi request reprint A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer
    Srinivasan Madhusudan
    Cancer Research United Kingdom Medical Oncology Unit, University of Oxford, The Churchill, Oxford Radcliffe Hospitals, Headington, Oxford, United Kingdom
    Clin Cancer Res 10:6528-34. 2004
    ..In the current study, we sought to determine the toxicity, biological activity, and therapeutic efficacy of Etanercept in metastatic breast cancer...
  22. ncbi request reprint Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer
    Srinivasan Madhusudan
    Cancer Research UK Medical Oncology Unit, University of Oxford, Churchill Hospital, Oxford, United Kingdom
    J Clin Oncol 23:5950-9. 2005
    ..In the current study, we sought to determine the toxicity, biologic activity, and therapeutic efficacy of etanercept in recurrent ovarian cancer...
  23. ncbi request reprint Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007
    Alan Ashworth
    Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Gynecol Oncol 108:652-7. 2008
    ..As ovarian cancer becomes a chronic disease, greater emphasis will be placed on the challenges facing survivors...
  24. ncbi request reprint RalB signaling: a bridge between inflammation and cancer
    Alberto Mantovani
    Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano and University of Milan, Italy
    Cell 127:42-4. 2006
    ..In tumor cells the RalB/TBK1 pathway inhibits apoptosis and in nontumorigenic cells it stimulates an innate immune response...
  25. ncbi request reprint Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma
    David J Propper
    Imperial Cancer Research Fund Medical Oncology Unit, University of Oxford, Churchill Hospital, Oxford X3 7LJ
    Clin Cancer Res 9:84-92. 2003
    ..The durable and long-lived responses, clear demonstration of tumor MHC up-regulation, and low toxicity suggest that weekly IFN-gamma 100 microg/m(2) would be a useful addition to chemoimmunotherapeutic regimens...